Pacritinib citrate

Drug Overview

Pacritinib citrate (marketed under the brand name Vonjo™) is a potent, oral, small-molecule multitargeted kinase inhibitor. It is specifically designed to inhibit Janus kinase 2 (JAK2), interleukin-1 receptor-associated kinase 1 (IRAK1), and Fms-like tyrosine kinase 3 (FLT3).

In the clinical landscape of March 2026, pacritinib is recognized as a breakthrough therapy for patients with myelofibrosis (MF) complicated by severe thrombocytopenia (low platelet counts). Myelofibrosis is a rare bone marrow cancer where healthy tissue is replaced by scar tissue, leading to an enlarged spleen and a dangerous drop in blood cell production.

While other JAK inhibitors (like ruxolitinib) often worsen low platelet counts, pacritinib is unique because it is “JAK1-sparing.” By selectively targeting JAK2 and IRAK1 without significantly inhibiting JAK1, it provides anti-inflammatory and anti-tumor effects while allowing for safer dosing in patients with platelet counts below 50 x 10⁹/L. Originally developed by CTI BioPharma (now part of Sobi), pacritinib was granted accelerated approval by the FDA in 2022 and remains the primary choice for “cytopenic” myelofibrosis in 2026.

• Generic Name: Pacritinib citrate.
• Brand Name: Vonjo™.
• Drug Class: Kinase Inhibitor; JAK2/IRAK1/ACVR1 Inhibitor.
• Mechanism: Selective inhibition of JAK2 and IRAK1 signaling pathways, reducing inflammation and tumor growth while sparing JAK1-mediated hematopoiesis.
• Route of Administration: Oral (Capsule).
• FDA Approval Status: FDA-approved (Accelerated approval: February 2022). It is approved for adults with intermediate or high-risk primary or secondary myelofibrosis and a platelet count below 50 x 10⁹/L.

What Is It and How Does It Work? (Mechanism of Action)

Pacritinib works through a “triple-action” blockade of the pathways that drive bone marrow scarring and cancer cell survival.

1. Selective JAK2 Inhibition

The JAK-STAT pathway is a major signaling route for cell growth. In myelofibrosis, mutations (like JAK2 V617F) keep this pathway “stuck” in the on position.

• The Target: Pacritinib binds to both wild-type and mutant JAK2.
• The Benefit: By shutting down this signal, it reduces the overproduction of abnormal cells and shrinks the enlarged spleen (splenomegaly).

2. IRAK1 and ACVR1 Inhibition (The Inflammation & Anemia Benefit)

Unlike many other inhibitors, pacritinib also blocks IRAK1 and ACVR1.

• Reducing Fibrosis: Blocking IRAK1 interferes with the NF-κB pathway, which drives the chronic inflammation and bone marrow fibrosis (scarring) seen in MF.
• Improving Anemia: Recent 2024–2025 research has highlighted that pacritinib inhibits ACVR1, which lowers hepcidin levels. Lower hepcidin allows the body to better use iron to make red blood cells, helping to improve the anemia that often plagues these patients.

3. Sparing JAK1

Standard “pan-JAK” inhibitors block JAK1, which is necessary for the body to produce platelets and fight infection.

• Myelo-Friendly: Because pacritinib “spares” JAK1, it does not cause the severe drops in platelets seen with other drugs, making it the only JAK inhibitor that can be started at a full therapeutic dose in patients with very low platelets.

Clinical Indications and Research Status (2026)

As of early 2026, pacritinib is the standard of care for specific patient populations:

• Cytopenic Myelofibrosis: Specifically for patients with primary or secondary (post-polycythemia vera or post-essential thrombocythemia) MF with platelets <50 x 10⁹/L.
• Anemic Myelofibrosis: Based on results from the PERSIST-2 and PACIFICA trials, pacritinib is increasingly used in patients whose primary symptom is severe, transfusion-dependent anemia.
• Confirmatory Trials: In mid-2025, data from the confirmatory PACIFICA trial helped solidify the clinical benefit required for the drug’s full FDA conversion, confirming long-term spleen volume reduction and symptom improvement.
• Other Myeloproliferative Neoplasms (MPNs): 2026 research is exploring its use in “blast-phase” MPNs and in combination with other agents to prevent progression to leukemia.

Dosage and Administration Protocols

Pacritinib is administered as an oral capsule that should be taken consistently to maintain pathway suppression.

Safety Profile and Side Effects

While pacritinib is safer for platelets, it has a distinct side effect profile that requires monitoring.

1. Gastrointestinal (GI) Effects

• Diarrhea: The most common side effect (approx. 48% of patients). It usually occurs within the first few weeks of treatment.
• Nausea/Vomiting: Generally mild but common during the initial phases.

2. Hemorrhage and Bleeding

Because patients taking pacritinib already have low platelets, there is an increased risk of bleeding.

• Precaution: Treatment should be held 7 days before any planned surgery or invasive dental procedure to reduce the risk of major bleeding.

3. Cardiac and QTc Prolongation

• Heart Rhythm: Pacritinib can cause changes in the heart’s electrical cycle (QTc prolongation). Baseline EKG and monitoring of electrolytes (potassium and magnesium) are mandatory.

4. Other Side Effects

• Peripheral Edema: Swelling of the hands and feet.
• Infection Risk: While lower than JAK1 inhibitors, there is still a risk of pneumonia or shingles reactivation.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, pacritinib is being used to study “Clonal Evolution.” Researchers are investigating if early use of JAK2/IRAK1 inhibition can stop the “evolution” of a pre-cancerous stem cell into a full-blown leukemic cell. In 2026, there is also intense focus on “Iron Mobilization,” using pacritinib as a model to understand how targeting the ACVR1/hepcidin axis can treat other chronic inflammatory diseases beyond cancer.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Complete Blood Count (CBC): Mandatory to confirm platelet levels.
• Baseline EKG: To check the QTc interval (must be <480 msec).
• Electrolyte Panel: Ensure potassium levels are normal to protect the heart.

“Do’s and Don’ts” List:

• DO keep an anti-diarrheal (like loperamide) on hand when starting treatment; most GI issues resolve within the first two weeks.
• DO tell your doctor immediately if you have a “pounding heart” or “fainting spells.”
• DON’T take pacritinib with grapefruit juice or strong CYP3A4 inhibitors (like clarithromycin), as they can dangerously increase the drug’s levels in your blood.
• DON’T stop the medication abruptly without a doctor’s guidance, as myelofibrosis symptoms can return rapidly (rebound effect).

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Pacritinib (Vonjo) is a potent kinase inhibitor that must be used under the guidance of a hematologist/oncologist. Always consult with your healthcare provider regarding your specific blood counts, potential drug interactions (including herbal supplements like turmeric), and surgical planning.